Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Safety and Tolerability Study of T-1101 (Tosylate) as a Oral Powder for Constitution (OPC) in Patients With Advanced Refractory Solid Tumors

NCT03195764 is registered in ClinicalTrials.gov with Taivex Therapeutics Corporation as lead sponsor.

NCT NCT03195764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03195764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Safety and Tolerability Study of T-1101 (Tosylate) as a Oral Powder for Constitution (OPC) in Patients With Advanced Refractory Solid Tumors
Lead sponsor
Taivex Therapeutics Corporation
Phase
Phase 1
Overall status
Terminated
Start date
September 14, 2017
Completion date
October 23, 2019
Enrollment
21 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced refractory solid tumors